HIVMA and IDSA are working with the National Coalition of STD Directors (NCSD) and Treatment Action Group (TAG) to address supply and cost issues affecting our response to the growing STI epidemic. ID, HIV and primary care providers, health department STD programs, and consumers are encouraged to use this new tool to help us track any issues related to accessing BPG and other STI medications.

HIVMA commented to the House Committee on Oversight and Government Reform that limiting or barring the use of fetal tissue in current and future research will be a major setback to important work to develop an HIV cure and vaccine and to develop more effective HIV medications.

HIVMA, IDSA, PIDS and RWMPC submitted public comments to the Department of Homeland Security, asking the administration to seriously consider implications of the “public charge” rule on health of immigrants and their families and access to treatment preventive services for communicable diseases, and to withdraw the proposed rule.